These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 22393833

  • 1. Antibacterial activity of clarithromycin loaded PLGA nanoparticles.
    Valizadeh H, Mohammadi G, Ehyaei R, Milani M, Azhdarzadeh M, Zakeri-Milani P, Lotfipour F.
    Pharmazie; 2012 Jan; 67(1):63-8. PubMed ID: 22393833
    [Abstract] [Full Text] [Related]

  • 2. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system.
    Mohammadi G, Nokhodchi A, Barzegar-Jalali M, Lotfipour F, Adibkia K, Ehyaei N, Valizadeh H.
    Colloids Surf B Biointerfaces; 2011 Nov 01; 88(1):39-44. PubMed ID: 21752610
    [Abstract] [Full Text] [Related]

  • 3. Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori.
    Lotfipour F, Valizadeh H, Milani M, Bahrami N, Ghotaslou R.
    Drug Res (Stuttg); 2016 Jan 01; 66(1):41-5. PubMed ID: 25919643
    [Abstract] [Full Text] [Related]

  • 4. Preparation and antibacterial activity of compound chitosan-compound Yizhihao-nanoparticles.
    Ou S, Zhang YD.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 May 01; 33(5):369-74. PubMed ID: 18544838
    [Abstract] [Full Text] [Related]

  • 5. Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.
    Jeong YI, Na HS, Seo DH, Kim DG, Lee HC, Jang MK, Na SK, Roh SH, Kim SI, Nah JW.
    Int J Pharm; 2008 Mar 20; 352(1-2):317-23. PubMed ID: 18160236
    [Abstract] [Full Text] [Related]

  • 6. Comparative evaluation of antibacterial activity of caffeic acid phenethyl ester and PLGA nanoparticle formulation by different methods.
    Arasoglu T, Derman S, Mansuroglu B.
    Nanotechnology; 2016 Jan 15; 27(2):025103. PubMed ID: 26629915
    [Abstract] [Full Text] [Related]

  • 7. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori.
    Jain SK, Haider T, Kumar A, Jain A.
    AAPS PharmSciTech; 2016 Oct 15; 17(5):1131-40. PubMed ID: 26566630
    [Abstract] [Full Text] [Related]

  • 8. Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria.
    Azhdarzadeh M, Lotfipour F, Zakeri-Milani P, Mohammadi G, Valizadeh H.
    Adv Pharm Bull; 2012 Oct 15; 2(1):17-24. PubMed ID: 24312766
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives.
    Liang JH, Wang YY, Wang H, Li XL, An K, Xu YC, Yao GW.
    Bioorg Med Chem Lett; 2010 May 01; 20(9):2880-3. PubMed ID: 20356738
    [Abstract] [Full Text] [Related]

  • 10. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery.
    Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G.
    J Drug Target; 2011 Jul 01; 19(6):409-17. PubMed ID: 20678034
    [Abstract] [Full Text] [Related]

  • 11. Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi.
    Mohammadi G, Valizadeh H, Barzegar-Jalali M, Lotfipour F, Adibkia K, Milani M, Azhdarzadeh M, Kiafar F, Nokhodchi A.
    Colloids Surf B Biointerfaces; 2010 Oct 01; 80(1):34-9. PubMed ID: 20558048
    [Abstract] [Full Text] [Related]

  • 12. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles.
    Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinarvand R.
    Nanomedicine; 2007 Jun 01; 3(2):161-7. PubMed ID: 17468055
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan 01; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli.
    Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S.
    Nanomedicine; 2007 Jun 01; 3(2):168-71. PubMed ID: 17468052
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of erythromycin and clarithromycin against clinical isolates of Escherichia coli, Staphylococcus aureus, Klebsiella and Proteus by disc diffusion method.
    Khan NW, Hassan F, Naqvi BS, Hasan SM.
    Pak J Pharm Sci; 2011 Jan 01; 24(1):25-9. PubMed ID: 21190914
    [Abstract] [Full Text] [Related]

  • 16. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
    Pandya M, Chakrabarti A, Rathy S, Katoch R, Venkataraman R, Bhateja P, Mathur T, Kumar GR, Malhotra S, Rao M, Bhadauria T, Barman TK, Das B, Upadhyay D, Bhatnagar PK.
    Int J Antimicrob Agents; 2010 Aug 01; 36(2):169-74. PubMed ID: 20493666
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains.
    Ma S, Jiao B, Ju Y, Zheng M, Ma R, Liu L, Zhang L, Shen X, Ma C, Meng Y, Wang H, Qi Y, Ma X, Cui W.
    Eur J Med Chem; 2011 Feb 01; 46(2):556-66. PubMed ID: 21159410
    [Abstract] [Full Text] [Related]

  • 18. Bacterial effects and protein corona evaluations: crucial ignored factors in the prediction of bio-efficacy of various forms of silver nanoparticles.
    Ashkarran AA, Ghavami M, Aghaverdi H, Stroeve P, Mahmoudi M.
    Chem Res Toxicol; 2012 Jun 18; 25(6):1231-42. PubMed ID: 22551528
    [Abstract] [Full Text] [Related]

  • 19. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
    Chu CH, Wang YC, Huang HY, Wu LC, Yang CS.
    Nanotechnology; 2011 May 06; 22(18):185601. PubMed ID: 21415469
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
    Nord CE, Lindmark A, Persson I.
    J Chemother; 1989 Jul 06; 1(4 Suppl):203-4. PubMed ID: 16312369
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.